- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02354872
Motivation Project: Testing Intervention Components for the Smoker Who is Unwilling to Quit
September 17, 2020 updated by: University of Wisconsin, Madison
Optimized Chronic Care for Smokers: A Comparative Effectiveness Approach; Motivation Project: Testing Intervention Components for the Smoker Who is Unwilling to Quit
The ultimate goal of this research is to develop a chronic care treatment package for smokers that will address the challenges and opportunities of each phase of the cessation process - motivation, preparation, cessation, maintenance, and relapse recovery.
That is, to develop treatments for smokers not yet ready to quit, those who are preparing to quit, those actively engaged in the quitting process and those who have tried to quit but relapsed.
To achieve this goal, this research comprises three distinct research studies, each of which represent a phase in a comprehensive chronic care treatment model for clinical intervention with smokers in the primary care setting: the Motivation Study, the Cessation Study, and the Long-term Quitting Study.
The goal of each study is to test and identify effective intervention components for distinct phases of the smoking cessation process.
These components will then be combined for future research on the effectiveness of this chronic care treatment package.
This study is a 2x2x2x2 factorial design.
Participants will be randomized to one of two levels on four different factors: 1) Nicotine Mini-Lozenge vs.
No Mini-Lozenge, 2) Behavioral Reduction Counseling (intervention: BR) vs.
No Behavioral Reduction Counseling, 3) 5Rs Motivation Counseling (intervention 5 R's) vs.
No 5Rs Motivation Counseling, and 4) Behavioral Activation Counseling (intervention BA) vs.
No Behavioral Activation Counseling.
These components have strong theoretical and empirical support, but their relative, additive, and interactive effects are unknown.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
577
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53711-2027
- University of Wisconsin Center for Tobacco Research and Intervention, School of Medicine and Public Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age >=18 years; smoking >4 cigarettes/day for the previous 6 months; able to read, write, and speak English; have reliable phone access and agree to respond to Interactive Voice Response (IVR) phone prompts; and if currently using NRT, agreeing to use only study medication for the duration of the study. We will not exclude participants based on their prior use of cessation medication or if they use multiple tobacco products in order to enhance real-world generalization (these will be statistically controlled in analyses); not currently attempting to quit smoking; not intending to quit smoking (defined as no plans to quit in the next month); and planning to remain in the intervention catchment area for at least 12 months.
Exclusion Criteria:
- currently taking bupropion or varenicline; medical contraindications to using NRT including hospitalized (for at least one night) for a stroke, heart attack, congestive heart failure or diabetes in the last 30 days; diagnosis of or treatment for schizophrenia, a psychotic disorder or bipolar disorder in the last 10 years; and, if the participant is a woman of childbearing potential, being pregnant or intending to becoming pregnant or unwillingness to use an approved method of birth control during treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mini-Lozenge, BR, 5Rs, BA
1; This arm of the project will address the following question: How effective is the following intervention?
Mini-Lozenge, BR, 5Rs, BA
|
If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges.
Mini-Lozenges will be given at the initial visit and over the course of the whole study.
Participants will be instructed to use 9 pieces daily for the 12 months.
We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions.
Sessions are front-loaded to enhance acquisition of new behaviors.
BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time.
BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control.
The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals.
The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period.
Participants in the "on" condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation.
The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis.
The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions.
This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction.
Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking.
The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
|
Experimental: Mini-Lozenge, BR, 5Rs, No BA
2; This arm of the project will address the following question: How effective is the following intervention?
Mini-Lozenge, BR, 5Rs, No BA
|
If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges.
Mini-Lozenges will be given at the initial visit and over the course of the whole study.
Participants will be instructed to use 9 pieces daily for the 12 months.
We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions.
Sessions are front-loaded to enhance acquisition of new behaviors.
BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time.
BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control.
The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals.
The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period.
Participants in the "on" condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation.
The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis.
The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
|
Experimental: Mini-Lozenge, BR, No 5Rs, BA
3; This arm of the project will address the following question: How effective is the following intervention?
Mini-Lozenge, BR, No 5Rs, BA
|
If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges.
Mini-Lozenges will be given at the initial visit and over the course of the whole study.
Participants will be instructed to use 9 pieces daily for the 12 months.
We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions.
Sessions are front-loaded to enhance acquisition of new behaviors.
BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time.
BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control.
The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals.
The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions.
This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction.
Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking.
The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
|
Experimental: Mini-Lozenge, BR, No 5Rs, No BA
4; This arm of the project will address the following question: How effective is the following intervention?
Mini-Lozenge, BR, No 5Rs, No BA
|
If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges.
Mini-Lozenges will be given at the initial visit and over the course of the whole study.
Participants will be instructed to use 9 pieces daily for the 12 months.
We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions.
Sessions are front-loaded to enhance acquisition of new behaviors.
BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time.
BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control.
The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals.
The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
|
Experimental: Mini-Lozenge, No BR, 5Rs, BA
5; This arm of the project will address the following question: How effective is the following intervention?
Mini-Lozenge, No BR, 5Rs, BA
|
If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges.
Mini-Lozenges will be given at the initial visit and over the course of the whole study.
Participants will be instructed to use 9 pieces daily for the 12 months.
The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period.
Participants in the "on" condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation.
The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis.
The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions.
This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction.
Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking.
The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
|
Experimental: Mini-Lozenge, No BR, 5Rs, No BA
6; This arm of the project will address the following question: How effective is the following intervention?
Mini-Lozenge, No BR, 5Rs, No BA
|
If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges.
Mini-Lozenges will be given at the initial visit and over the course of the whole study.
Participants will be instructed to use 9 pieces daily for the 12 months.
The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period.
Participants in the "on" condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation.
The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis.
The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
|
Experimental: Mini-Lozenge, No BR, No 5Rs, BA
7; This arm of the project will address the following question: How effective is the following intervention?
Mini-Lozenge, No BR, No 5Rs, BA
|
If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges.
Mini-Lozenges will be given at the initial visit and over the course of the whole study.
Participants will be instructed to use 9 pieces daily for the 12 months.
The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions.
This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction.
Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking.
The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
|
Experimental: Mini-Lozenge, No BR, No 5Rs, No BA
8; This arm of the project will address the following question: How effective is the following intervention?
Mini-Lozenge, No BR, No 5Rs, No BA
|
If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges.
Mini-Lozenges will be given at the initial visit and over the course of the whole study.
Participants will be instructed to use 9 pieces daily for the 12 months.
|
Experimental: No Mini-Lozenge, BR, 5Rs, BA
9; This arm of the project will address the following question: How effective is the following intervention?
No Mini-Lozenge, BR, 5Rs, BA
|
We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions.
Sessions are front-loaded to enhance acquisition of new behaviors.
BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time.
BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control.
The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals.
The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period.
Participants in the "on" condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation.
The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis.
The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions.
This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction.
Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking.
The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
|
Experimental: No Mini-Lozenge, BR, 5Rs, No BA
10; This arm of the project will address the following question: How effective is the following intervention?
No Mini-Lozenge, BR, 5Rs, No BA
|
We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions.
Sessions are front-loaded to enhance acquisition of new behaviors.
BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time.
BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control.
The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals.
The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period.
Participants in the "on" condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation.
The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis.
The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
|
Experimental: No Mini-Lozenge, BR, No 5Rs, BA
11; This arm of the project will address the following question: How effective is the following intervention?
No Mini-Lozenge, BR, No 5Rs, BA
|
We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions.
Sessions are front-loaded to enhance acquisition of new behaviors.
BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time.
BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control.
The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals.
The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions.
This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction.
Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking.
The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
|
Experimental: No Mini-Lozenge, BR, No 5Rs, No BA
12; This arm of the project will address the following question: How effective is the following intervention?
No Mini-Lozenge, BR, No 5Rs, No BA
|
We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions.
Sessions are front-loaded to enhance acquisition of new behaviors.
BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time.
BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control.
The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals.
The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
|
Experimental: No Mini-Lozenge, No BR, 5Rs, BA
13; This arm of the project will address the following question: How effective is the following intervention?
No Mini-Lozenge, No BR, 5Rs, BA
|
The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period.
Participants in the "on" condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation.
The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis.
The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions.
This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction.
Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking.
The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
|
Experimental: No Mini-Lozenge, No BR, 5Rs, No BA
14; This arm of the project will address the following question: How effective is the following intervention?
No Mini-Lozenge, No BR, 5Rs, No BA
|
The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period.
Participants in the "on" condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation.
The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis.
The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
|
Experimental: No Mini-Lozenge, No BR, No 5Rs, BA
15; This arm of the project will address the following question: How effective is the following intervention?
No Mini-Lozenge, No BR, No 5Rs, BA
|
The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions.
This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction.
Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking.
The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
|
Experimental: No Mini-Lozenge, No BR, No 5Rs, No BA
16; This arm of the project will address the following question: How effective is the following intervention?
No Mini-Lozenge, No BR, No 5Rs, No BA
|
No Treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
7-Day Point-Prevalence Abstinence
Time Frame: 12 months
|
Participants who self-report no smoking for the past 7 days at the assessment endpoint (12 month follow-up) will be considered to meet criteria for 7-Day Point-Prevalence Abstinence.
Participants who who report any smoking in the past 7 days (at the 12 month follow-up) will be considered to be relapsed (smoking).
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Michael C Fiore, MD, MPH, MBA, University of Wisconsin Center for Tobacco Research and Intervention, School of Medicine and Public Health
- Study Director: Jessica Cook, PhD, University of Wisconsin Center for Tobacco Research and Intervention, School of Medicine and Public Health
- Principal Investigator: Robin Mermelstein, PhD, Institute for Health Research and Policy, University of Illinois at Chicago
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
March 19, 2019
Study Completion (Actual)
March 19, 2019
Study Registration Dates
First Submitted
January 22, 2015
First Submitted That Met QC Criteria
January 29, 2015
First Posted (Estimate)
February 3, 2015
Study Record Updates
Last Update Posted (Actual)
September 22, 2020
Last Update Submitted That Met QC Criteria
September 17, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-1041Motivation
- A534252 (Other Identifier: UW Madison)
- CTRI (Other Identifier: UW Madison)
- SMPH\MEDICINE\TOBACCO RE (Other Identifier: UW Madison)
- 1P01CA180945-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Columbia UniversityNational Cancer Institute (NCI)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking BehaviorsUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
Maastricht University Medical CenterThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Medical University of South CarolinaRecruitingSmoking | Smoking Cessation | Tobacco Smoking | Cigarette SmokingUnited States
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI); New York University; Stanford UniversityRecruitingSmoking | Smoking, Tobacco | Smoking, CigaretteUnited States
Clinical Trials on No Treatment
-
HealthpointCompletedVenous Leg Ulcer (VLU)Germany, Poland, Belgium, Hungary, Czechia
-
HealthpointCompleted
-
University Hospital, GrenobleUnknownObstructive Sleep Apnea Syndrome | HypertensionFrance
-
Anna Alessandri BonettiCompletedPain | Sleep Apnea Syndromes | Sleep Apnea, Obstructive | Sleep Apnea | Temporomandibular Disorder | Pain, FaceItaly
-
Guangzhou Medical UniversityThe Children's Hospital of Zhejiang University School of Medicine; Gansu Provincial... and other collaboratorsRecruiting
-
National Cancer Institute (NCI)Active, not recruitingBrain Cancer | Brain Tumor | Neoplasm | Spine Cancer | Spine TumorUnited States
-
Rigshospitalet, DenmarkNovo Nordisk A/SCompletedDepression | Brain Diseases | Quality of Life | Physical ImpairmentDenmark
-
University College, LondonWellcome Trust; National Institute for Health Research, United KingdomUnknownMyocardial Infarction | Heart Failure | Stroke | Ischemic Stroke | Peripheral Arterial Disease | Transient Ischemic Attack | Stable Angina Pectoris | Unstable Angina | Abdominal Aortic Aneurysm | Intracerebral Haemorrhage | Subarachnoid Haemorrhage | Coronary Heart Disease NOS | Unheralded Corronary Death | Cardiac...United Kingdom
-
AllerganCompleted